[CLOSED] Public consultation on the position paper on how to decide on the appropriate study design for primary research arising from HTA
In order to gather as much feedback as possible, WP7 Subgroup 2 has decided to extend the public consultation period on the Position paper on how to decide on the appropriate study design until May 29, 2015 at 12:00 noon
The Joint Assessment on “Ramucirumab (Cyramza®) in combination with Paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction adenocarcinoma” available
WP5-SA4 – Updated report including the complete dataset on indirect comparisons published on EUnetHTA homepage. Find the Joint Assessment here.
Following the agreed schedule of biannual meetings between EUnetHTA and the EMA, the next meeting is held tomorrow (May 8, 2015) in London The final draft agenda for the meeting is available here. The minutes of the meeting will be made publicly
The 2nd JA2 methodological guideline has now been published You can find the methodological guideline and the comments and provided answers in the output section.